Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Innovation in Antibody-Drug Conjugates (ADCs)
share announcement

Innovation in Antibody-Drug Conjugates (ADCs)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 9065

Special Issue Editors

Prof. Dr. Naoto T. Ueno

E-Mail Website
Guest Editor
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: ADC, tumor microenvironment, phase I, phase II, aggressive breast cancer, inflammatory breast cancer, triple-negative breast cancer
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Jennifer Maynard

E-Mail Website
Guest Editor
1. Department of Biochemistry, The University of Texas at Austin, Austin, TX 78712, USA
2. McKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA
Interests: biotechnology; protein therapeutics; vaccine development; applied immunology and microbiology

Special Issue Information

Dear Colleagues,

The recent approval by many regulatory boards of various Antibody-drug conjugates (ADC) had a dramatic improvement in the outcome of cancer patients. Since the first approval of ADC more than 20 years ago, there has been a major effort to improve its efficacy of ADC. This overall efficacy ADC is defined by antibody, linker, and payload. Further, these factors will impact the overall toxicities. This Special Issue of ADC allows us to present the latest research related to ADC and collectively show the future of ADC research direction. We are pleased to invite you to address the innovative approach to treating cancer by ADC, novel modification, and the translational and clinical impact of ADC in cancer management.

Prof. Dr. Naoto T. Ueno
Prof. Dr. Jennifer Maynard
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibody
  • cancer
  • linker
  • payload

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

26 pages, 2045 KiB  
Review
Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma
by Ali Al Sbihi, Maryam Alasfour and Georgios Pongas
Cancers 2024, 16(4), 827; https://doi.org/10.3390/cancers16040827 - 18 Feb 2024
Viewed by 1429
Abstract
Chemoimmunotherapy and cellular therapy are the mainstay of the treatment of relapsed/refractory (R/R) lymphomas. Development of resistance and commonly encountered toxicities of these treatments limit their role in achieving desired response rates and durable remissions. The Antibody–Drug Conjugate (ADC) is a novel class [...] Read more.
Chemoimmunotherapy and cellular therapy are the mainstay of the treatment of relapsed/refractory (R/R) lymphomas. Development of resistance and commonly encountered toxicities of these treatments limit their role in achieving desired response rates and durable remissions. The Antibody–Drug Conjugate (ADC) is a novel class of targeted therapy that has demonstrated significant efficacy in treating various cancers, including lymphomas. To date, three ADC agents have been approved for different lymphomas, marking a significant advancement in the field. In this article, we aim to review the concept of ADCs and their application in lymphoma treatment, provide an analysis of currently approved agents, and discuss the ongoing advancements of ADC development. Full article
(This article belongs to the Special Issue Innovation in Antibody-Drug Conjugates (ADCs))
►▼ Show Figures

Figure 1

20 pages, 2370 KiB  
Review
Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs
by Virginia Metrangolo and Lars H. Engelholm
Cancers 2024, 16(2), 447; https://doi.org/10.3390/cancers16020447 - 20 Jan 2024
Viewed by 7149
Abstract
Introduced almost two decades ago, ADCs have marked a breakthrough in the targeted therapy era, providing clinical benefits to many cancer patients. While the inherent complexity of this class of drugs has challenged their development and broad application, the experience gained from years [...] Read more.
Introduced almost two decades ago, ADCs have marked a breakthrough in the targeted therapy era, providing clinical benefits to many cancer patients. While the inherent complexity of this class of drugs has challenged their development and broad application, the experience gained from years of trials and errors and recent advances in construct design and delivery have led to an increased number of ADCs approved or in late clinical development in only five years. Target and payload diversification, along with novel conjugation and linker technologies, are at the forefront of next-generation ADC development, renewing hopes to broaden the scope of these targeted drugs to difficult-to-treat cancers and beyond. This review highlights recent trends in the ADC field, focusing on construct design and mechanism of action and their implications on ADCs’ therapeutic profile. The evolution from conventional to innovative ADC formats will be illustrated, along with some of the current hurdles, including toxicity and drug resistance. Future directions to improve the design of next-generation ADCs will also be presented. Full article
(This article belongs to the Special Issue Innovation in Antibody-Drug Conjugates (ADCs))
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop